Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Iqvia 559K share Block Trade priced at $263.00 » 08:28
11/30/21
11/30
08:28
11/30/21
08:28
IQV

Iqvia

$266.56 /

+3.78 (+1.44%)

The deal range was…

The deal range was $263.00-$264.00. Morgan Stanley acted as sole book running manager for the offering.

ShowHide Related Items >><<
IQV Iqvia
$266.56 /

+3.78 (+1.44%)

IQV Iqvia
$266.56 /

+3.78 (+1.44%)

11/18/21 BofA
Iqvia added to US 1 list at BofA
11/18/21 Mizuho
Iqvia price target raised to $290 from $282 at Mizuho
11/18/21 Piper Sandler
Iqvia price target raised to $261 from $250 at Piper Sandler
11/17/21 KeyBanc
Iqvia price target raised to $290 from $270 at KeyBanc
IQV Iqvia
$266.56 /

+3.78 (+1.44%)

  • 30
    Nov
Monday
Syndicate
Iqvia 559K share Block Trade; price range $263.00-$264.00 » 16:49
11/29/21
11/29
16:49
11/29/21
16:49
IQV

Iqvia

$266.56 /

+3.78 (+1.44%)

Morgan Stanley is acting…

Morgan Stanley is acting as sole book running manager for the offering.

ShowHide Related Items >><<
IQV Iqvia
$266.56 /

+3.78 (+1.44%)

IQV Iqvia
$266.56 /

+3.78 (+1.44%)

11/18/21 BofA
Iqvia added to US 1 list at BofA
11/18/21 Mizuho
Iqvia price target raised to $290 from $282 at Mizuho
11/18/21 Piper Sandler
Iqvia price target raised to $261 from $250 at Piper Sandler
11/17/21 KeyBanc
Iqvia price target raised to $290 from $270 at KeyBanc
IQV Iqvia
$266.56 /

+3.78 (+1.44%)

Over a week ago
Recommendations
Iqvia added to US 1 list at BofA » 09:26
11/18/21
11/18
09:26
11/18/21
09:26
IQV

Iqvia

$264.46 /

-3.165 (-1.18%)

BofA says its US 1 list…

BofA says its US 1 list is intended to represent a collection of the best investment ideas drawn from the firm's Buy-rated, US-listed stocks covered by BofA Global Research fundamental equity research analysts.

ShowHide Related Items >><<
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

IQV Iqvia
$264.46 /

-3.165 (-1.18%)

11/18/21 Mizuho
Iqvia price target raised to $290 from $282 at Mizuho
11/18/21 Piper Sandler
Iqvia price target raised to $261 from $250 at Piper Sandler
11/17/21 KeyBanc
Iqvia price target raised to $290 from $270 at KeyBanc
11/17/21 Citi
Iqvia price target raised to $320 from $300 at Citi
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

Recommendations
Iqvia price target raised to $290 from $282 at Mizuho » 06:38
11/18/21
11/18
06:38
11/18/21
06:38
IQV

Iqvia

$264.46 /

-3.165 (-1.18%)

Mizuho analyst Ann Hynes…

Mizuho analyst Ann Hynes raised the firm's price target on Iqvia to $290 from $282 and keeps a Buy rating on the shares post the investor day. Iqvia raised its intermediate growth target for revenue and adjusted EBITDA by 250 basis points at the midpoint, and maintained double-digit adjusted earnings growth, Hynes tells investors in a research note. The analyst believes the company's earnings visibility remains high in the near- to mid-term.

ShowHide Related Items >><<
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

IQV Iqvia
$264.46 /

-3.165 (-1.18%)

11/18/21 Piper Sandler
Iqvia price target raised to $261 from $250 at Piper Sandler
11/17/21 KeyBanc
Iqvia price target raised to $290 from $270 at KeyBanc
11/17/21 Citi
Iqvia price target raised to $320 from $300 at Citi
11/17/21 UBS
Iqvia price target raised to $310 from $298 at UBS
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

Recommendations
Iqvia price target raised to $261 from $250 at Piper Sandler » 04:56
11/18/21
11/18
04:56
11/18/21
04:56
IQV

Iqvia

$264.46 /

-3.165 (-1.18%)

Piper Sandler analyst…

Piper Sandler analyst Sean Wieland raised the firm's price target on Iqvia to $261 from $250 and keeps a Neutral rating on the shares following the investor day. The company laid out a vision for $20B in revenue by fiscal 2025, Wieland tells investors in a research note. The analyst says that while sales momentum has been strong and ahead of targets, he's concerned about Covid revenue tailwinds subsiding as well as rising wages and retention costs.

ShowHide Related Items >><<
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

IQV Iqvia
$264.46 /

-3.165 (-1.18%)

11/17/21 KeyBanc
Iqvia price target raised to $290 from $270 at KeyBanc
11/17/21 Citi
Iqvia price target raised to $320 from $300 at Citi
11/17/21 UBS
Iqvia price target raised to $310 from $298 at UBS
11/12/21 Evercore ISI
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list
IQV Iqvia
$264.46 /

-3.165 (-1.18%)

Recommendations
Iqvia price target raised to $290 from $270 at KeyBanc » 07:49
11/17/21
11/17
07:49
11/17/21
07:49
IQV

Iqvia

$267.63 /

+15.835 (+6.29%)

KeyBanc analyst Donald…

KeyBanc analyst Donald Hooker raised the firm's price target on Iqvia to $290 from $270 and keeps an Overweight rating on the shares after management hosted an Investor Day at which it provided a better-than-expected top- and bottom-line growth outlook for the next 3-plus years. The analyst now sees Iqvia generating low-teens EBITDA growth in 2022 and 2023, despite the loss of $1B-plus of revenue in 2022 due to the completion of large COVID-19 clinical trials. The wind-down of these large COVID-19 clinical trials had been a concern for 2022, Hooker notes

ShowHide Related Items >><<
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

IQV Iqvia
$267.63 /

+15.835 (+6.29%)

11/17/21 Citi
Iqvia price target raised to $320 from $300 at Citi
11/17/21 UBS
Iqvia price target raised to $310 from $298 at UBS
11/12/21 Evercore ISI
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list
10/28/21 Mizuho
Iqvia price target raised to $282 from $270 at Mizuho
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

Recommendations
Iqvia price target raised to $320 from $300 at Citi » 07:25
11/17/21
11/17
07:25
11/17/21
07:25
IQV

Iqvia

$267.63 /

+15.835 (+6.29%)

Citi analyst Patrick…

Citi analyst Patrick Donnelly raised the firm's price target on Iqvia to $320 from $300 and keeps a Buy rating on the shares. During its investor day, the company discussed its initial 2022 guidance and 2022-2025 medium term outlook, highlighting the "robust" biopharma backdrop and its favorable position for hybrid clinical trials as key growth drivers, Donnelly tells investors in a research note.

ShowHide Related Items >><<
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

IQV Iqvia
$267.63 /

+15.835 (+6.29%)

11/17/21 UBS
Iqvia price target raised to $310 from $298 at UBS
11/12/21 Evercore ISI
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list
10/28/21 Mizuho
Iqvia price target raised to $282 from $270 at Mizuho
10/27/21 Deutsche Bank
Iqvia price target raised to $282 from $250 at Deutsche Bank
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

Recommendations
Iqvia price target raised to $310 from $298 at UBS » 06:58
11/17/21
11/17
06:58
11/17/21
06:58
IQV

Iqvia

$267.63 /

+15.835 (+6.29%)

UBS analyst Dan Brennan…

UBS analyst Dan Brennan raised the firm's price target on Iqvia to $310 from $298 and keeps a Buy rating on the shares. The company's investor day presentation was "upbeat" with initial FY22 guidance and updated long-term targets coming ahead of estimates, the analyst tells investors in a research note. Brennan adds that he continues to see an attractive opportunity given accelerating growth, share gains, and the positive industry backdrop.

ShowHide Related Items >><<
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

IQV Iqvia
$267.63 /

+15.835 (+6.29%)

11/12/21 Evercore ISI
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list
10/28/21 Mizuho
Iqvia price target raised to $282 from $270 at Mizuho
10/27/21 Deutsche Bank
Iqvia price target raised to $282 from $250 at Deutsche Bank
10/22/21 Stifel
Iqvia price target raised to $304 from $300 at Stifel
IQV Iqvia
$267.63 /

+15.835 (+6.29%)

Conference/Events
Iqvia to hold a meeting » 09:29
11/16/21
11/16
09:29
11/16/21
09:29
IQV

Iqvia

$251.82 /

-2.89 (-1.13%)

Financial Analyst and…

Financial Analyst and Investor Meeting to be held on November 16 at 10 am. Webcast Link

ShowHide Related Items >><<
IQV Iqvia
$251.82 /

-2.89 (-1.13%)

IQV Iqvia
$251.82 /

-2.89 (-1.13%)

11/12/21 Evercore ISI
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list
10/28/21 Mizuho
Iqvia price target raised to $282 from $270 at Mizuho
10/27/21 Deutsche Bank
Iqvia price target raised to $282 from $250 at Deutsche Bank
10/22/21 Stifel
Iqvia price target raised to $304 from $300 at Stifel
IQV Iqvia
$251.82 /

-2.89 (-1.13%)

Recommendations
Evercore ISI raises Iqvia price target to $320, adds to tactical outperform list » 08:44
11/12/21
11/12
08:44
11/12/21
08:44
IQV

Iqvia

$252.56 /

+0.42 (+0.17%)

Evercore ISI analyst…

Evercore ISI analyst Elizabeth Anderson raised the firm's price target on Iqvia to $320 from $300 and keeps an Outperform rating on the shares while adding the stock to Evercore ISI's TAP Outperform list ahead of the company's investor day next Tuesday, November 16. She sees upside to Street estimates for 2022 and also views the investor day as an opportunity for management to provide a deeper dive that should give investors greater certainty into the TAS segment's outlook, Anderson said.

ShowHide Related Items >><<
IQV Iqvia
$252.56 /

+0.42 (+0.17%)

IQV Iqvia
$252.56 /

+0.42 (+0.17%)

10/28/21 Mizuho
Iqvia price target raised to $282 from $270 at Mizuho
10/27/21 Deutsche Bank
Iqvia price target raised to $282 from $250 at Deutsche Bank
10/22/21 Stifel
Iqvia price target raised to $304 from $300 at Stifel
10/22/21 Citi
Iqvia price target raised to $300 from $280 at Citi
IQV Iqvia
$252.56 /

+0.42 (+0.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.